Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Merck KGaA buys neuroinflammation firm Chord Therapeutics

by Michael McCoy
January 2, 2022 | A version of this story appeared in Volume 100, Issue 1

The structure of cladribine.

Merck KGaA has acquired the Swiss start-up Chord Therapeutics for an undisclosed sum. Chord launched in 2020 with $16 million in funding to develop cladribine for the treatment of two rare neuroinflammatory diseases. Merck already markets cladribine under the name Mavenclad as a treatment for relapsing multiple sclerosis. The German firm says Chord will help it expand its pipeline of neurology drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.